It Seems Viking Therapeutics Incorporated (NASDAQ:VKTX) Will Go Down. Just Reported More Shorted Shares

August 16, 2017 – By Nellie Frank

The stock of Viking Therapeutics Incorporated (NASDAQ:VKTX) registered an increase of 38.16% in short interest. VKTX’s total short interest was 555,400 shares in August as published by FINRA. Its up 38.16% from 402,000 shares, reported previously. With 211,100 shares average volume, it will take short sellers 3 days to cover their VKTX’s short positions. The short interest to Viking Therapeutics Incorporated’s float is 3.5%.

The stock increased 3.00% or $0.03 on August 16, reaching $1.03. About 41,443 shares traded. Viking Therapeutics Inc (NASDAQ:VKTX) has risen 5.04% since August 16, 2016 and is uptrending. It has underperformed by 11.66% the S&P500.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $28.53 million. The Firm focuses on the development of therapies for metabolic and endocrine disorders. It currently has negative earnings. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

Viking Therapeutics Inc (NASDAQ:VKTX) Ratings Coverage

Among 3 analysts covering Viking Therapeutics (NASDAQ:VKTX), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Viking Therapeutics had 8 analyst reports since April 7, 2016 according to SRatingsIntel. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, August 10 report. Maxim Group maintained Viking Therapeutics Inc (NASDAQ:VKTX) on Thursday, August 10 with “Buy” rating. As per Tuesday, June 6, the company rating was maintained by Maxim Group. Maxim Group initiated the stock with “Buy” rating in Tuesday, May 24 report. The stock has “Buy” rating by Laidlaw on Thursday, August 11. H.C. Wainwright initiated Viking Therapeutics Inc (NASDAQ:VKTX) rating on Thursday, April 7. H.C. Wainwright has “Buy” rating and $6 target. The firm has “Buy” rating by Maxim Group given on Wednesday, July 12. The stock has “Buy” rating by H.C. Wainwright on Monday, July 17.

More notable recent Viking Therapeutics Inc (NASDAQ:VKTX) news were published by: Seekingalpha.com which released: “Viking Therapeutics’ (VKTX) Brian Lian on Q1 2017 Results – Earnings Call …” on May 11, 2017, also Prnewswire.com with their article: “Viking Therapeutics and PoC Capital Enter Agreement to Fund Clinical …” published on February 14, 2017, Prnewswire.com published: “Viking Therapeutics Doses First Patient in Phase 2 Clinical Trial of VK2809 in …” on October 04, 2016. More interesting news about Viking Therapeutics Inc (NASDAQ:VKTX) were released by: Prnewswire.com and their article: “Viking Therapeutics to Report Financial Results for Fourth Quarter and Year …” published on March 02, 2017 as well as Prnewswire.com‘s news article titled: “Viking Therapeutics Announces Promising Top Line Results from In Vivo Study of …” with publication date: June 06, 2017.